Tessera Therapeutics Attracts Over $230M in Series B Financing to Advance ‘Gene Writing’ – A New Category in Genetic Medicine
Jan 12, 2021•over 4 years ago
Amount Raised
$230 Million
Round Type
series b
Description
Tessera Therapeutics, an early-stage life sciences company founded by Flagship Pioneering, announced today that it has raised over $230M in Series B financing. The round was co-led by Alaska Permanent Fund Corporation, Altitude Life Science Ventures, and SoftBank Vision Fund 2i, with participation from Qatar Investment Authority (QIA) and others.
FundzWatch™ Score
83
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech